A GLP-1 Started Before Surgery Lightens the Patient, Not the Result

A timing-stratified review of 27 studies finds preoperative GLP-1 drugs improve weight loss before the operation but not after it, that early postoperative use adds a few points, and that rescue therapy after regain rests on the only randomised trials — while a small Chicago cohort finds no postoperative benefit at all.

GLP-1bariatric surgeryweight lossresearch

Patients who take a GLP-1 drug in the months before bariatric surgery arrive at the operating table lighter. What that head start is worth afterwards is a separate question, and the answer that emerges from a timing-stratified systematic review published on 25 October is easy to misread as an arithmetic trick: once the clock is restarted at the day of surgery, the patients who had taken the drug beforehand lost slightly less of their body weight over the following year than those who had not.

The review, published in Chinese in the Chinese Journal of Gastrointestinal Surgery, sorted 27 clinical studies into three windows — before the operation, shortly after it, and as rescue therapy once weight loss had stalled or reversed — and pooled 13 of them quantitatively. Read as three separate questions rather than one, the literature stops looking contradictory and starts looking chronological.

The pre-surgery window

Ten of the included studies examined preoperative use, and on its own terms that use works. Pooled across them, patients who started a GLP-1 receptor agonist before surgery lost more weight before the operation, with a standardised mean difference of 0.52 (95% CI 0.25–0.79) and no detectable heterogeneity between studies.

The trouble starts when the measurement is repeated afterwards. Using body weight on the day of surgery as the baseline, twelve-month total weight loss was 2.85 percentage points lower in the preoperative-medication group (95% CI −4.35 to −1.36; I² = 37.7%). In other words, the lighter patient stayed lighter in absolute terms but had less distance left to travel once the anaesthetic wore off. Whether that counts as a failure or as a denominator effect is the kind of question that has bitten this field before: the choice of baseline can decide who looks like a suboptimal responder, as an earlier look at weight-loss metrics after bariatric surgery showed. The review’s authors are careful to phrase it as an absence of postoperative additional benefit, not as harm.

What the later windows show

The postoperative strata behave differently, and more conventionally. Starting a GLP-1 about a month after surgery added 3.62 percentage points of twelve-month weight loss at the six-month mark (95% CI 1.88–5.37; I² = 0%), and starting one around six months after surgery produced an extra 7.48 kg of loss over subsequent follow-up (95% CI 5.35–9.60; I² = 34.6%).

Rescue therapy is where the evidence becomes a different animal. Four randomised controlled trials in the review compared a GLP-1 against placebo or usual care in patients whose weight loss had fallen short or reversed, and the pooled additional endpoint weight loss was 10.30 percentage points (95% CI 6.40–14.20). That is the largest effect in the paper and the only stratum built on randomisation — though heterogeneity of 89.2% means the trials were not describing the same patients, dose or duration, and a pooled figure that wide is a direction rather than a prescription.

A Chicago cohort that found nothing

Against that gradient sits a small single-institution analysis from Rush University Medical Center, published in the November issue of the Journal of Surgical Research. The authors identified 808 adults who had a sleeve or a bypass between July 2022 and June 2024, of whom 29 started semaglutide or tirzepatide within a year of surgery — the mean start was about 7.8 months postoperatively — and 779 did not.

After propensity-score matching on baseline characteristics and on early postoperative weight loss, there was no statistically significant difference in weight outcomes at two weeks or at three, six or twelve months in either procedure group (P ≥ 0.07). In the sleeve group the numbers ran in the expected direction, 22.6% total weight loss against 18.3%, without reaching significance. The study is exploratory and tiny on the exposed side, and matching on early weight loss deliberately removes part of the effect a drug is meant to produce. But the direction of the discrepancy is worth naming: a Polish single-centre series of 88 sleeve patients published this month found that semaglutide started at six months did produce significantly greater weight loss at twelve and twenty-four months, and the pooled review agrees with the Polish series, not with Chicago. Two observational cohorts, opposite answers, and nothing randomised in the middle.

The part the pooled numbers leave out

Where the review is unambiguous is tolerability. Among studies that reported event counts, pooled rates were 25.3% for nausea, 19.0% for constipation, 9.2% for diarrhoea and 8.6% for vomiting, with serious adverse events described as uncommon. It did not pool pulmonary or aspiration outcomes, which is precisely the concern that makes preoperative use a scheduling question as much as a metabolic one: delayed gastric emptying can leave retained contents in the stomach, and a narrative review in Advances in Anesthesia treats that risk, not weight loss, as the organising problem of the perioperative period.

What the field still lacks is the trial that would settle the timing question directly — patients randomised at the operating table, with the clock, the baseline and the endpoint fixed in advance, rather than three observational strata compared across 27 heterogeneous studies. The LABS cohort, funded by NIDDK, was built to answer exactly this kind of longitudinal question about surgery; the equivalent design for drugs layered onto surgery does not yet exist. Until it does, the timing of a GLP-1 looks less like a detail of prescription practice and more like the variable that determines what the evidence says.

This archive is independent of NIH and NIDDK and reports published research only; nothing here is medical advice.

Sources

  1. Efficacy and safety of GLP-1 receptor agonists combined with bariatric surgery for obesity: a timing-stratified systematic review (Chinese Journal of Gastrointestinal Surgery, published online 25 October 2026)
  2. Adjuvant glucagon-like peptide-1 receptor agonist therapy post-bariatric surgery: an exploratory single-institution analysis (Journal of Surgical Research, November 2026)
  3. The impact of semaglutide initiated six months after laparoscopic sleeve gastrectomy on long-term weight loss and metabolic outcomes: single-center preliminary study (Surgical Endoscopy, published online 8 October 2026)
  4. An updated review of glucagon-like peptide-1 receptor agonists: perioperative implications, guidance statements, and current literature (Advances in Anesthesia, December 2026)
From the blog

New research notes